

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
20 February 2003 (20.02.2003)

PCT

(10) International Publication Number  
**WO 03/013529 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/4525** (74) Agent: WEST, Vivien; GlaxoSmithKline, Corporate Intellectual Property CN925.1, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(21) International Application Number: PCT/EP02/08926

(22) International Filing Date: 9 August 2002 (09.08.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0119467.9 9 August 2001 (09.08.2001) GB

(71) Applicant (for all designated States except US):  
SMITHKLINE BEECHAM PLC. [GB/GB]; 980 Great West Road, Brentford, Middlesex, TW8 9GS (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BARGES CAUSERET, Nathalie, Claude, Marianne [FR/FR]; Laboratoire GlaxoSmithKline, ZI du Terras, BP 2, F-53101 Mayenne Cedex (FR). MARZOLINI, Nicola, Lisa, Anna [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW (GB). MENEAUD, Padma [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex, CM19 5AW (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPo patent (GH, GM, KE, LS, MW, MZ, SD, SL, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 03/013529 A1**

(54) Title: PAROXETINE GLYCIRRHIZINATE

(57) Abstract: A salt formed from paroxetine hydrochloride and ammonium glycyrrhizinate masks the bitter taste of paroxetine and has a distinctive liquorice flavour.

**PAROXETINE GLYCYRRHIZINATE**

The present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders.

Pharmaceutical products with antidepressant and anti-Parkinson properties are described in US-A-3912743 and US-A-4007196. An especially important compound among those disclosed is paroxetine, the (*-trans*) isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxy-phenoxymethyl)-piperidine. This compound is used in therapy as the hydrochloride salt for the treatment and prophylaxis of *inter alia* depression, obsessive compulsive disorder (OCD) and panic.

We have now surprisingly discovered a novel salt of paroxetine with glycyrrhyzic acid which may be used as an alternative to the currently marketed hydrochloride.

According to the present invention there is provided paroxetine glycyrhizinate as a novel compound.

A great advantage of the glycyrhizinate salt in oral formulations is its intense flavour of sweet liquorice which provides a taste-masking effect to hide the bitterness of paroxetine. In fact, because of the intensity of the liquorice flavour, further flavourings may be desirable to modify the liquorice taste of the formulation.

In one aspect the novel salt of this invention is provided in non-crystalline form, which may be a solid or an oil. The oil is preferably absorbed on a solid carrier, especially a carrier that is usable as a component of a pharmaceutical composition.

In another aspect the novel salt of this invention is provided in crystalline form. When the crystalline form exists as more than one polymorph, each polymorph forms another aspect of this invention.

Paroxetine glycyrrhizinate may be prepared by contacting stoichiometric amounts of the acid and paroxetine free base. Preferably the base is in solution, more preferably both are in solution.

Most commonly used solvents are suitable for mobilising paroxetine free base, for example toluene, alcohols such as methanol, ethanol, propan-2-ol, esters such as ethyl acetate, ketones such as acetone and butanone, halogenated hydrocarbons such as dichloromethane, and ethers such as tetrahydrofuran and diethyl ether. The glycyrrhizinic acid is preferably added as an aqueous or ethanolic solution. The glycyrrhizinic acid may also be added in the form of a soluble salt, for example ammonium glycyrrhizinate, or the glycyrrhizinic acid salt of an amine, for example ethylamine or diethylamine.

The concentration of paroxetine base is preferably in the range 5 to 50% weight/volume, more preferably in the range 10 to 30%. The concentration of glycyrrhizinic acid is suitably in the same range. Elevated temperatures may be used to increase solubility.

The salt may be isolated in solid form by conventional means from a solution thereof obtained as above. For example, a non-crystalline salt may be prepared by precipitation from solution, spray drying and freeze drying of solutions, evaporating a solution to a glass, or vacuum drying of oils, or solidification of melts obtained from reaction of the free base and the acid.

A crystalline salt may be prepared by directly crystallising from a solvent in which the product has limited solubility, or by triturating or otherwise crystallising a non-crystalline salt. An improved yield of the salt is obtained by evaporation of some or all of the solvent or by crystallisation at elevated temperature followed by controlled cooling, preferably in stages. Careful control of precipitation temperature and seeding may be used to improve the reproducibility of the production process and the particle size distribution and form of the product. Individual polymorphs are preferably crystallized directly from a solution of the salt, although recrystallizing a solution of one polymorph using seeds of another polymorph may also be carried out.

An alternative method of preparing paroxetine glycyrhizinate is to start with a salt of paroxetine with an organic acid, such as acetic acid or maleic acid, rather than using paroxetine free base. Use of another salt of paroxetine as a starting material is suitable for preparation of the crystalline salt or, if a volatile acid such as acetic acid is used, non-crystalline salts by methods that involve evaporation (such as freeze-drying and spray-drying).

We have found it particularly effective to combine paroxetine hydrochloride with ammonium glycyrhizinate.

The salt may be obtained as a solvate, when during isolation from solution it becomes associated with the solvent in which it is dissolved. Any such solvate forms a further aspect of this invention. Solvates may be returned to the unsolvated salt by heating, for example by oven-drying, or by treatment with a displacement solvent which does not form a solvate.

Prior to the isolation of the paroxetine glycyrhizinate, water may be removed from the solution containing the salt by azeotropic distillation to avoid the formation of hydrates or to obtain the product in anhydrous form. In that case, suitable solvents for the solution of the salt are those which form an azeotrope with water such as toluene and propan-2-ol. It should also be appreciated that mixtures of solvents can also be used to aid the azeotropic removal of water.

Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0223403. Glycyrrhizinic acid is commercially available as the mono-ammonium, disodium and dipotassium salts.

The compounds of this invention may be used to treat and prevent the following disorders:

Alcoholism

Anxiety

Depression

Obsessive Compulsive Disorder

Panic Disorder	Chronic Pain
Obesity	Senile Dementia
Migraine	Bulimia
Anorexia	Social Phobia
Pre-Menstrual Syndrome (PMS)	Adolescent Depression
Trichotillomania	Dysthymia
Substance Abuse	

These disorders are herein after referred to as "the Disorders".

The present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a salt of the invention to a sufferer in need thereof.

The present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of the Disorders which comprises an admixture of a salt of the invention with a pharmaceutically acceptable carrier.

The present invention also provides the use of a salt of the invention for treating and/or preventing the Disorders.

The present invention also provides the use of a salt of the invention in the manufacture of a medicament for treating and/or preventing the Disorders.

Most suitably the present invention is applied to the treatment of depression, OCD and panic.

Compositions containing the salt of this invention may be formulated for administration by any route, and examples are oral, sub-lingual, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of the paroxetine salt.

The medicaments may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.

- 5 The composition is usually presented as a unit dose composition containing from 1 to 200mg of paroxetine calculated from the amount of salt on a free base basis, more usually from 5 to 100mg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of paroxetine calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for
- 10 example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of paroxetine calculated on a free base basis. Most preferably the unit dose is taken once a day.

15 The compositions of the invention are usually adapted for oral administration; preferred unit dosage forms include tablets or capsules.

- The compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
- 20 Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilized in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
  - 25 Specific examples of pharmaceutical compositions include those described EP-B-0223403 and US 4,007,196, in which the products of the present invention may be used as the active ingredients.

The following Examples illustrate the present invention:

30

**Example 1 : preparation of tablets**

INGREDIENTS	20 mg Tablet	30mg Tablet
Paroxetine Glycyrrhizinate	20.00 mg (calc. as free base)	30.0 mg (calc. as free base)
Dicalcium Phosphate (DCP)	83.34 mg	125.0 mg
Microcrystalline Cellulose	50.67 mg	76.0 mg
Sodium Starch Glycollate	8.34 mg	12.5 mg
Magnesium Stearate	1.67 mg	2.5 mg

## Commercial source of the ingredients

- 5              Dicalcium Phosphate Dihydrate        -        Emcompress or Ditab\*
- Microcrystalline Cellulose        -        Avicel PH 102\*
- Sodium Starch Glycollate        -        Explotab.\*

\* Trade names

## 10     Method

1. Pass DCP through a screen and weigh it into a Planetary mixer.
2. Add 30 mesh Paroxetine Glycyrrhizinate to the bowl.
3. Add 20 mesh Avicel and Explotab and mix all the powders for 10 minutes.
4. Add magnesium stearate and mix for 5 minutes.

15

## Tablet into Pentagonal Tablets using the following punches:

- |              |         |              |
|--------------|---------|--------------|
| 30 mg Tablet | 9.5 mm  | Circumcircle |
| 20 mg Tablet | 8.25 mm | Circumcircle |

- 20     The tablets are made satisfactorily on a single punch or a Rotary press.

**Example 2 : preparation of tablets**

INGREDIENTS	10 mg Tablet	20 mg Tablet	30mg Tablet
Paroxetine Glycyrrhizinate	10 mg (calc.as free base)	20 mg (calc.as free base)	30 mg (calc.as free base)
Sodium Starch Glycollate	2.98 mg	5.95 mg	8.93 mg
Granular Dicalcium Phosphate (DITAB) or Dicafos	158.88 mg	317.75 mg	476.63 mg
Magnesium Stearate	1.75 mg	3.50 mg	5.25 mg

5

**Method**

1. Paroxetine Glycyrrhizinate, Sodium Starch Glycollate and Dicalcium Phosphate Dihydrate are screened and mixed together in a suitable mixer.  
(Planetary, Cuble or High Energy Shear mixer.)
- 10 2. Add Magnesium Stearate and compress it into a tablet using a single punch or Rotary Tablet machine.

**CLAIMS**

1. A paroxetine glycyrrhizinate salt.
- 5 2. A compound according to claim 1 in non-crystalline form.
3. A compound according to claim 1 in crystalline form.
4. A process for the preparation of a compound as claimed in claim 1 or 2 by precipitation from a solution of a paroxetine glycyrrhizinate, spray drying or freeze drying a solution of a paroxetine glycyrrhizinate, evaporating a solution of a paroxetine glycyrrhizinate to a glass, or by vacuum drying of oils of a paroxetine glycyrrhizinate, or solidification of melts of a paroxetine glycyrrhizinate.
- 15 5. A process for the preparation of a compound as claimed in claim 1 or 3 by crystallization or re-crystallization from a solution of a paroxetine glycyrrhizinate.
6. A process according to claim 4 or 5 in which the solution, oil or melt of a paroxetine glycyrrhizinate is prepared by treating paroxetine free base or an organic acid salt thereof with glycyrrhizinic acid or an ammonium or amine salt thereof.
- 20 7. A method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a paroxetine glycyrrhizinate to a sufferer in need thereof.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 02/08926

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61K31/4525

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 15155 A (FRANCESE FRANCO ;OLDANI DIEGO (IT); MANESCHI MASSIMO (IT); SMITHKL) 8 June 1995 (1995-06-08) abstract page 1, line 24 – line 26 page 2, line 6 – line 8 page 2, line 14 claims 1-7 ---	1-7
Y	DATABASE REGISTRY 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; RN:1405-86-3, "Glycyrrhizin" XP002225024 the whole document ---	1-7 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report:

16 December 2002

10/01/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenttaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Fax. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Giacobbe, S

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/08926

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 811 436 A (COOPER DAVID ET AL) 22 September 1998 (1998-09-22) claims 1-9 column 1, line 31 - line 39 column 1, line 50 - line 54 -----	1-7
A	DE 201 00 529 U (SYNTHON B.V., NIJMEGEN, NL) 13 June 2001 (2001-06-13) page 8, paragraph 2 -----	
A	US 4 393 200 A (MIYASHITA AKIRA ET AL) 12 July 1983 (1983-07-12) column 1, paragraph 2 -----	1-7
A	US 5 763 449 A (FAWZY ABDEL A ET AL) 9 June 1998 (1998-06-09) abstract -----	1-7
P,Y	WO 02 074238 A (LAVIPHARM LAB INC) 26 September 2002 (2002-09-26) claims 1-44 abstract -----	1-7

**INTERNATIONAL SEARCH REPORT**International application No.  
PCT/EP 02/08926**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claim 7 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this International application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/08926

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9515155	A	08-06-1995	IT AU AU CA CN WO EP JP NZ ZA	MI932540 A1 693144 B2 1219895 A 2177721 A1 1145586 A 9515155 A1 0804168 A1 9505818 T 277238 A 9409567 A		05-06-1995 25-06-1998 19-06-1995 08-06-1995 19-03-1997 08-06-1995 05-11-1997 10-06-1997 27-04-1998 10-10-1995
US 5811436	A	22-09-1998	AU AU BG BG BR DE DE DK EP FI GR HK JP NO NZ PL RO RU SI SK AP AP AT CN CZ WO ES HU IL TW ZA	682091 B2 1536895 A 62843 B1 100763 A 9507055 A 69508924 D1 69508924 T2 742715 T3 0742715 A1 963051 A 3030131 T3 1012288 A1 9508402 T 963244 A 278891 A 315679 A1 116342 B 2136281 C1 742715 T1 100496 A3 536 A 611 A 178489 T 1140411 A ,B 9602293 A3 9520964 A1 2129806 T3 75941 A2 112521 A 436296 B 9500776 A		18-09-1997 21-08-1995 29-09-2000 31-03-1997 02-09-1997 12-05-1999 21-10-1999 18-10-1999 20-11-1996 01-08-1996 30-07-1999 12-05-2000 26-08-1997 02-08-1996 26-01-1998 25-11-1996 30-01-2001 10-09-1999 31-08-1999 04-12-1996 26-09-1996 03-09-1997 15-04-1999 15-01-1997 15-01-1997 10-08-1995 16-06-1999 28-05-1997 22-09-1999 28-05-2001 01-08-1996
DE 20100529	U	10-05-2001	DE WO	20100529 U1 02055062 A2		10-05-2001 18-07-2002
US 4393200	A	12-07-1983	JP JP JP JP FR GB	56113793 A 1610300 C 2022080 B 56115797 A 2473526 A1 2071665 A ,B		07-09-1981 15-07-1991 17-05-1990 11-09-1981 17-07-1981 23-09-1981
US 5763449	A	09-06-1998	AU AU EP JP US	727175 B2 3913297 A 0938302 A1 2000505093 T 5962461 A		07-12-2000 25-02-1998 01-09-1999 25-04-2000 05-10-1999

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/08926

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
US 5763449	A	WO	9805312	A1	12-02-1998
WO 02074238	A	26-09-2002	WO US	02074238 A2 2002147201 A1	26-09-2002 10-10-2002